Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET

Molecular Imaging and Biology

Volumn 12, Issue 6, 2010, Pages 616-625

  Pantaleo, Maria A ^a   Mishani, Eyal ^b   Nanni, Cristina ^a   Landuzzi, Lorena ^c   Boschi, Stefano ^a   Nicoletti, Giordano ^c   Dissoki, Samar ^b   Paterini, Paola ^d   Piccaluga, Pier Poalo ^a   Lodi, Filippo ^a   Lollini, Pier Luigi ^a   Fanti, Stefano ^a   Biasco, Guido ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Laboratory of Oncologic Research   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Epidermal growth factor receptor (EGFR); Small animal PET; Tyrosine kinase (TK) inhibitors

Indexed keywords

CARBON 11; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORINE 18; IODINE 124; POLYETHYLENE GLYCOL ANILINOQUINAZOLINE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER CELL CULTURE; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; HUMANS; MICE; MICE, NUDE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MOLECULAR IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 78650516740     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0315-z     Document Type: Article

References (36)

1. Y Yarden 2001 The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities Eur J Cancer 37 Suppl 4 S3 S8 1:CAS:528:DC%2BD3MXntlOku78%3D 10.1016/S0959-8049(01)00230-1 11597398 (Pubitemid 32938123)
2. J Baselga 2001 The EGFR as a target for anticancer therapy-focus on cetuximab Eur J Cancer 37 Suppl 4 S16 S22 1:CAS:528:DC%2BD3MXntlOku70%3D 10.1016/S0959-8049(01)00233-7 11597400 (Pubitemid 32938125)
3. DS Salomon R Brandt F Ciardiello N Normanno 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Critical Rev Oncol Hematol 19 183 232 1:STN:280:DyaK2Mzjs1KgsQ%3D%3D 10.1016/1040-8428(94) 00144-I
4. SV Sharma DW Bell J Settleman DA Haber 2007 Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 169 181 1:CAS:528: DC%2BD2sXitVGrsbo%3D 10.1038/nrc2088 17318210 (Pubitemid 46316032)
5. RI Nicholson JM Gee ME Harper 2001 EGFR and cancer prognosis Eur J Cancer 37 Suppl 4 S9 S15 1:CAS:528:DC%2BD3MXntlOku7w%3D 10.1016/S0959-8049(01)00231-3 11597399
6. F Ciardiello G Tortora 2008 EGFR antagonists in cancer treatment N Engl J Med 358 1160 1174 1:CAS:528:DC%2BD1cXjt1ahsL4%3D 10.1056/NEJMra0707704 18337605 (Pubitemid 351398490)
7. W Cai G Niu X Chen 2008 Multimodality imaging of the HER-kinase axis in cancer Eur J Nucl Med Mol Imaging 35 186 208 10.1007/s00259-007-0560-9 17846765 (Pubitemid 350234146)
8. E Mishani G Abourbeh 2007 Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFr) Curr Top Med Chem 7 1755 1772 1:CAS:528:DC%2BD2sXhsVOrtb3M 10.2174/156802607782507457 17979785 (Pubitemid 350130995)
9. MA Pantaleo M Nannini A Maleddu, et al. 2009 Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer Ann Oncol 20 213 226 1:STN:280:DC%2BD1M7jtlWltQ%3D%3D 10.1093/annonc/mdn625 18842614
10. A Fredriksson P Johnström JO Thorell, et al. 1999 In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants Life Sci 65 165 174 1:CAS:528:DyaK1MXktFais70%3D 10.1016/S0024-3205(99)00233-7 10416822 (Pubitemid 29292819)
11. TA Bonasera G Ortu Y Rozen, et al. 2001 Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase Nucl Med Biol 28 359 374 1:CAS:528:DC%2BD3MXktVOiu70%3D 10.1016/S0969-8051(01)00200-1 11395308 (Pubitemid 32520994)
12. I Ben-David Y Rozen G Ortu E Mishani 2003 Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride Appl Radiat Isot 58 209 217 1:CAS:528:DC%2BD3sXotlGqtQ%3D%3D 10.1016/S0969-8043(02)00301-9 12573320 (Pubitemid 36175491)
13. G Ortu I Ben-David Y Rozen, et al. 2002 Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug Int J Cancer 101 360 370 1:CAS:528:DC%2BD38XmvFWiu7Y%3D 10.1002/ijc.10619 12209961 (Pubitemid 34983192)
14. M Shaul G Abourbeh O Jacobson, et al. 2004 Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer Bioorg Med Chem 12 3421 3429 1:CAS:528:DC%2BD2cXks12ktLo%3D 10.1016/j.bmc.2004.04.044 15186828 (Pubitemid 38746846)
15. E Mishani G Abourbeh Y Rozen, et al. 2004 Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors Nucl Med Biol 31 469 476 1:CAS:528:DC%2BD2cXjt1SitL4%3D 10.1016/j.nucmedbio.2003.12.005 15093817 (Pubitemid 38490746)
16. E Mishani G Abourbeh O Jacobson, et al. 2005 High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors J Med Chem 48 5337 5348 1:CAS:528: DC%2BD2MXmtVWiu74%3D 10.1021/jm0580196 16078851 (Pubitemid 41113919)
17. G Abourbeh S Dissoki O Jacobson, et al. 2007 Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors Nucl Med Biol 34 55 70 1:CAS:528:DC%2BD2sXisVaisw%3D%3D 10.1016/j.nucmedbio.2006.10.012 17210462 (Pubitemid 46038157)
18. A Pal A Glekas M Doubrovin, et al. 2006 Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography Mol Imaging Biol 8 262 277 1:STN:280:DC%2BD28rmtlSitA%3D%3D 10.1007/s11307-006-0049-0 16897320 (Pubitemid 44446020)
19. Wang JQ, Gao M, Miller KD, Sledge GW, Zheng QH (2006) Synthesis of 11C-Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem 4102-4106 (Pubitemid 44425196)
20. M Wang M Gao BH Mock, et al. 2006 Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents Bioorg Med Chem 14 8599 8607 1:CAS:528:DC%2BD28XhtFOjt7jM 10.1016/j.bmc.2006.08. 026 16962783 (Pubitemid 44667526)
21. H Wang J Yu G Yang, et al. 2007 Assessment of 11C-labeled-4-N-(3- bromoanilino)-6, 7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression Cancer Sci 98 1413 1416 1:CAS:528:DC%2BD2sXhtVaksrvN 10.1111/j.1349-7006.2007.00562.x 17627611 (Pubitemid 47241765)
22. H Wang JM Yu GR Yang, et al. 2007 Further characterization of the epidermal growth factor receptor ligand 11C-PD153035 Chin Med J 120 960 964 1:CAS:528:DC%2BD2sXnvVGit7w%3D 17624262 (Pubitemid 46902174)
23. H Su Y Seimbille GZ Ferl, et al. 2008 Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors Eur J Nucl Med Mol Imaging 35 1089 1099 1:CAS:528:DC%2BD1cXlvVCltrY%3D 10.1007/s00259-007-0636-6 18239919
24. AA Memon S Jakobsen F Dagnaes-Hansen BS Sorensen S Keiding E Nexo 2009 Positron emission tomography (PET) imaging with 11C-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts Cancer Res 69 873 878 1:CAS:528:DC%2BD1MXhtFOkt7Y%3D 10.1158/0008-5472.CAN-08-3118 19155297
25. 11C-labeled PD153035 in humans J Nucl Med 50 303 308 10.2967/jnumed.108.056556 19164239
26. S Dissoki Y Aviv D Laky G Abourbeh A Levitzki E Mishani 2007 The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline- 6-YL]-amide moiety-an EGFR putative irreversible inhibitor Appl Radiat Isot 65 1140 1151 1:CAS:528:DC%2BD2sXpvVequro%3D 10.1016/j.apradiso.2007.04.014 17574425 (Pubitemid 47333371)
27. S Dissoki R Eshet H Billauer E Mishani 2009 Modified PEG- anilinoquinazoline derivatives as potential EGFR PET agents J Label Compd Radiopharm 52 41 52 1:CAS:528:DC%2BD1MXjt12ntrw%3D 10.1002/jlcr.1569
28. PP Piccaluga G Visani SA Pileri, et al. 2002 Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study Leukemia 16 1609 1614 1:CAS:528:DC%2BD38XmsV2lsbY%3D 10.1038/sj.leu.2402596 12200671
29. N Weidner JP Semple WR Welch J Folkman 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N Engl J Med 324 1 8 1:STN:280:DyaK3M%2FnsVWquw%3D%3D 10.1056/NEJM199101033240101 1701519 (Pubitemid 24058195)
30. AP Dei Tos 2007 The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor Int J Biol Biomarkers 22 S3 S9 1:STN:280:DC%2BD2szgvVyjsA%3D%3D
31. TJ Lynch DW Bell R Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 1:CAS:528: DC%2BD2cXktF2js7c%3D 10.1056/NEJMoa040938 15118073 (Pubitemid 38637993)
32. JG Paez PA Jänne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 1:CAS:528:DC%2BD2cXksVGmsbs%3D 10.1126/science.1099314 15118125 (Pubitemid 38720929)
33. CJ Allegra JM Jessup MR Somerfield, et al. 2009 American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2091 2096 10.1200/JCO.2009.21.9170 19188670
34. MA Pantaleo M Nannini S Fanti S Boschi P Lollini G Biasco 2009 Molecular imaging of EGFr: it's time to go beyond the receptor expression J Nucl Med 50 1195 1196 10.2967/jnumed.109.063909 19525453
35. RK Kancha N von Bubnoff C Peschel J Duyster 2009 Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy Clin Cancer Res 15 460 467 1:CAS:528: DC%2BD1MXlvFektg%3D%3D 10.1158/1078-0432.CCR-08-1757 19147750
36. MA Pantaleo S Fanti M Nannini, et al. 2008 What oncologists need and require from nuclear medicine Eur J Nucl Med Mol Imaging 35 1761 1765 1:STN:280:DC%2BD1cnhslKhug%3D%3D 10.1007/s00259-008-0825-y 18509632